Tyrosine Protein Kinase SYK – Pipeline Review, H1 2020 – ResearchAndMarkets.com

February 27, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Tyrosine Protein Kinase SYK – Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The latest report Tyrosine Protein Kinase SYK – Pipeline Review, H1 2020, outlays comprehensive information on the Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Companies Mentioned

  • AB Science SA
  • Archer Pharmaceuticals Inc
  • Asana BioSciences LLC
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Bristol-Myers Squibb Co
  • Clevexel Pharma SAS
  • Fujifilm Holdings Corp
  • Genosco Inc
  • Gilead Sciences Inc
  • GlaxoSmithKline Plc
  • Hutchison MediPharma Ltd
  • Japan Tobacco Inc
  • Levolta Pharmaceuticals Inc
  • Millennium Pharmaceuticals Inc
  • Nano Biotherapeutics Inc
  • Portola Pharmaceuticals Inc
  • Pulmatrix Inc
  • Rigel Pharmaceuticals Inc
  • Taiho Pharmaceutical Co Ltd
  • TopiVert Ltd

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) targeted therapeutics

Reasons to buy

  1. Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  2. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  3. Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2)
  4. Identify the use of drugs for target identification and drug repurposing
  5. Identify potential new clients or partners in the target demographic
  6. Develop strategic initiatives by understanding the focus areas of leading companies
  7. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  8. Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) development landscape
  9. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Topics Covered:

  • Introduction
  • Report Coverage
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Overview
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Companies Involved in Therapeutics Development
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Drug Profiles
  • AB-8779 – Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CC-509 – Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cerdulatinib – Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Dormant Products
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Discontinued Products
  • Tyrosine Protein Kinase SYK (Spleen Tyrosine Kinase or p72 Syk or SYK or EC 2.7.10.2) – Product Development Milestones
  • Featured News & Press Releases
  • Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/epy5e9

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900